STIM

Neuronetics Inc

Add to Watchlist

Advanced Chart

4.470

-0.05(-1.106%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.579942

Open

4.550

VWAP

Vol

574.61K

Mkt Cap

294.22M

Low

4.430

Amount

EV/EBITDA(TTM)

Total Shares

30.00M

333.41M

EV/OCF(TTM)

P/S(TTM)

1.99

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

43.86M

+98.45%

-0.015

-64.35%

38.22M

+106.25%

-0.065

-85.23%

36.94M

+124.58%

-0.080

-75.76%

Estimates Revision

The market is revising Upward the revenue expectations for Neuronetics, Inc. (STIM) for FY2025, with the revenue forecasts being adjusted by 0.24% over the past three months. During the same period, the stock price has changed by 2.05%.

Revenue Estimates for FY2025

Revise Upward

+0.24%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+17.03%

In Past 3 Month

Stock Price

Go Up

+2.05%

In Past 3 Month

1 Analyst Rating

78.97% Upside

Wall Street analysts forecast STIM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STIM is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

78.97% Upside

Current: 4.470

Low

8.00

Averages

8.00

High

8.00

78.97% Upside

Current: 4.470

Low

8.00

Averages

8.00

High

8.00

Citizens Capital Markets

Daniel Stauder

Buy

Maintains

$3 → $7

2025-03-05

Reason

Citizens Capital Markets

Daniel Stauder

Price Target

$3 → $7

2025-03-05

Maintains

Buy

Reason

Citizens JMP raised the firm's price target on Neuronetics to $7 from $3 and keeps an Outperform rating on the shares. Neuronetics' Top-line quarterly results came in moderately ahead of the company's mid-January preliminary announcement, and full-year 2025 guidance was maintained, the analyst tells investors in a research note. The stock's nearly 20% increase on Tuesday was most likely from additional commentary on what has been driving the stock higher year to date -- the potential growth, scale, and patient reach that the combined entity could achieve as a vertically integrated mental healthcare provider following the merger with Greenbrook TMS, the firm says.

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$5 → $8

2025-03-05

Reason

Canaccord Genuity

William Plovanic

Price Target

$5 → $8

2025-03-05

Maintains

Strong Buy

Reason

Canaccord raised the firm's price target on Neuronetics to $8 from $5 and keeps a Buy rating on the shares. The firm said they reported Q4 revenue which was slightly ahead of guidance and management reiterated guidance which was issued in January.

JMP Securities

David Turkaly

Buy

Maintains

$7 → $3

2024-08-14

Reason

JMP Securities

David Turkaly

Price Target

$7 → $3

2024-08-14

Maintains

Buy

Reason

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$6 → $3

2024-08-13

Reason

Canaccord Genuity

William Plovanic

Price Target

$6 → $3

2024-08-13

Maintains

Strong Buy

Reason

William Blair

Margaret Kaczor

Buy

Hold

Downgrades

n/a

2024-08-12

Reason

William Blair

Margaret Kaczor

Price Target

n/a

2024-08-12

Downgrades

Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Neuronetics Inc (STIM.O) is -21.02, compared to its 5-year average forward P/E of -5.62. For a more detailed relative valuation and DCF analysis to assess Neuronetics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.62

Current PE

-21.02

Overvalued PE

-0.32

Undervalued PE

-10.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.19

Current EV/EBITDA

-94.35

Overvalued EV/EBITDA

9.84

Undervalued EV/EBITDA

-38.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.95

Current PS

1.92

Overvalued PS

3.61

Undervalued PS

0.28